

## Disclosure of Directors and Senior Managers Relevant Interests

To NZX Limited; and	
Name of listed issuer:	Fisher 9 Device Healthcare Comparation Limited
Date this disclosure made:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure:	3 September 2021
Date of last disclosure.	15 September 2020
Director or senior manager giving disclosure	
Full name(s):	Andrew Robert Donald SOMERVELL
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	Not Applicable
Position held in listed issuer:	Vice President - Products & Technology
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)  Class of affected quoted financial products:  Nature of the affected relevant interest(s):	(a) Cancellation of Options and issue of Ordinary Shares (b) Issue and Exercise of Performance Share Rights Beneficia
For that relevant interest	
Number held in class before acquisition or disposal:	(a) 88,672 Options (b) 28,275 PSRs
Number held in class after acquisition or disposal:	(a) 109,826 Options (b) 35,676 PSRs
Current registered holder(s):	Andrew Robert Donald Somervel
Registered holder(s) once transfers are registered:	Andrew Robert Donald Somervell
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)	ole)
Type of affected derivative:	Not Applicable
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	<u> </u>
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	Two

Details of transactions requiring disclosure-	
Date of transaction:	(a) 01 September 2021 (b) 01 September 2021
Nature of transaction:	(a) Issue of Options (b) Issue of PSRs
Name of any other party or parties to the transaction (if known):	(2)
The consideration, expressed in New Zealand dollars, paid or received for the acquisition	
or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:	(a) \$nil (b) \$nil
	(a) Issue of 21,154 Options
Number of financial products to which the transaction related:  If the issuer has a financial products trading policy that prohibits directors or senior	(b) Issue of 7,401 PSRs
managers from trading during any period without written clearance (a closed period) include the following details—	
Whether relevant interests were aquired or disposed of during a closed period:	
Whether prior written clearance was provided to allow the aquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	Ordinary Shares
Nature of relevant interest:	Beneficial
For that relevant interest,-	
Number held in class:	80,779
Current registered holder(s):	Andrew Somervell
For a derivative relevant interest,-	
Type of derivative:	Not applicable
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant	
interest in the derivative:	
Cerification	
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	aroslu
Date of signature:	3 September 2021
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	
Name and title of authorised person:	



### Disclosure of Directors and Senior Managers Relevant Interests

To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	3 September 2021
Date of last disclosure:	14 September 2020
Director or senior manager giving disclosure	
Full name(s):	Lewis George GRADON
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Chief Executive Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)	
Class of affected quoted financial products:	(a) Options to acquire Ordinary Shares (b) Performance Share Rights
Nature of the affected relevant interest(s):	Beneficial Interest
For that relevant interest:	
Number held in class before acquisition or disposal:	(a) 309,071 Options to acquire Ordinary Shares (b) 98,492 Performance Share Rights
Number held in class after acquisition or disposal:	(a) 382,704 Options to acquire Ordinary Shares (b) 124,253 Performance Share Rights
Current registered holder(s):	Lewis George Gradon and Gradon Family Trust
Registered holder(s) once transfers are registered:	Lewis George Gradon and Gradon Family Trust
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable Type of affected derivative:	Not Applicable
Class of underlying financial products:	
Details of affected derivative:	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative:	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	Two
Details of transactions requiring disclosure:	,,,,,
Date of transaction:	(a) 01 September 2021 (b) 01 September 2021
Nature of transaction:	(a) Issue of Options to acquire Ordinary Shares (b) Issue of Performance Share Rights
Name of any other party or parties to the transaction (if known):	

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a	(a) \$nil
cash value, describe the consideration:	(b) \$nil (a) 73,633
Number of financial products to which the transaction related:	(b) 25,761
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details:	
Whether relevant interests were acquired or disposed of during a closed period:	
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	
Summary of other relevant interests after acquisition or disposal	
Class of quoted financial products:	Ordinary Shares
Nature of relevant interest:	Beneficial
For that relevant interest:	26.00.00
Number held in class:	556,776
Current registered holder(s):  For a derivative relevant interest:	Lewis George Gradon and Gradon Family Trust
	Not Applicable
Type of derivative:  Details of derivative:	Not Applicable
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest:	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Certification	
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	Lgado
Date of signature:	3 September 2021
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	
Name and title of authorised person:	



### Disclosure of Directors and Senior Managers Relevant Interests

	1
To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	3 September 2021
Date of last disclosure:	14 September 2020
Director or senior manager giving disclosure	
Full name(s):	Lyndal Jane York
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	Not Applicable
Position held in listed issuer:	Chief Financial Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivati	
Class of affected quoted financial products:	(a) Performance Share Rights (b) Options to acquire Ordinary Shares
Nature of the affected relevant interest(s):	Beneficial
For that relevant interest	
Number held in class before acquisition or disposal:	(a) 15,275 (b) 48,285
Number held in class after acquisition or disposal:	(a) 22,741 (b) 69,624
Current registered holder(s):	Lyndal Jane York
Registered holder(s) once transfers are registered:	Lyndal Jane York
Summary of acquisition or disposal of specified derivatives relevant interest (if appl	icable)
Type of affected derivative:	Not Applicable
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):  The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:  If the director or senior manager is not a party to the derivative, the nature of the relevant	
interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	1
Total number of transactions to which notice relates:	Two
Details of transactions requiring disclosure-	(a) 01 September 2021
Date of transaction:	(a) Issue of Performance Share Rights
Nature of transaction:	(b) Issue of Options to acquire Ordinary Shares
Name of any other party or parties to the transaction (if known):  The consideration, expressed in New Zealand dollars, paid or received for the acquisition	
or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	(a) \$0 (b) \$0

	(-) 7.400
Number of financial products to which the transaction related:  If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—	(a) 7,466 (b) 21,339
Whether relevant interests were aquired or disposed of during a closed period:	
Whether prior written clearance was provided to allow the aquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	Ordinary Shares
	·
Nature of relevant interest:	Beneficial
For that relevant interest,-	
Number held in class:	1,000
Current registered holder(s):	Alexander Eric York
For a derivative relevant interest,-	/ Hoxandor Eno Tork
Type of derivative:	Not Applicable
Details of derivative,-	тост ррносило
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Cerification	
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	ume_
Date of signature:	3 September 2021
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	
Name and title of authorised person:	



## Disclosure of Directors and Senior Managers Relevant Interests

To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	3 September 2021
Date of last disclosure:	2 December 2020
Director or senior manager giving disclosure	
Full name(s):	Paul Nigel Sheare
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Senior Vice President - Sales & Marketing
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)	
Class of affected quoted financial products:	(a) Options to acquire Ordinary Shares (b) Performance Share Rights
Nature of the affected relevant interest(s):	Beneficia
For that relevant interest-	
Number held in class before acquisition or disposal:	(a) 155,928 Options (b) 49,729 PSRs
Number held in class after acquisition or disposal:	(a) 192,112 Options (b) 62,388 PSRs
Current registered holder(s):	Paul Nigel Shearer and Shearer Family Trus
Registered holder(s) once transfers are registered:	Paul Nigel Shearer and Shearer Family Trus
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable	e)
Type of affected derivative:	Not Applicable
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	

Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	Two
Details of transactions requiring disclosure-	( ) 2 ( 2 )
Date of transaction:	(a) 01 September 2021 (b) 01 September 2021
Nature of transaction:	(a) Issue of Options to acquire Ordinary Shares (b) Issue of Performance Share Rights
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or recieved for the acquisition	( ) • "
or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	(a) \$nil (b) \$nil
	(a) 36,184
Number of financial products to which the transaction related:	(b) 12,659
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period)	
include the following details—	
Whether relevant interests were aquired or disposed of during a closed period:	
Whether prior written clearance was provided to allow the aquisition or disposal to	
proceed during the closed period:	
Date of the prior written clearance (if any):	
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	Ordinary Shares
Nature of relevant interest:	Beneficial
For that relevant interest,-  Number held in class:	356,460
Current registered holder(s):	Paul Nigel Shearer and Shearer Family Trust
For a derivative relevant interest,-	
Type of derivative:	Not Applicable
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Cerification	
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	PaulSteare
Date of signature:	3 September 2021
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	
Name and title of authorised person:	